Page 45 - Read Online
P. 45

Della Porta et al.                                                                                                                                                     Comparison of p53 and prohibitin expression

           Table 2: Comparative TNFR1, TRAIL, NFkB, nuclear RelA/p65, p53, nuclear PHB, cytoplasmic PHB and TUNEL
           expression by NL, CIR, HCV, and HCC
                                                   NL         HCV         CIR        HCC
           Markers              Expression                                                           P < 0.05
                                                 (n = 20)    (n = 30)   (n = 30)    (n = 60)
           TNFR1                  Negative         18          3           3          32
                                     +              2          24          9          13           CIR vs. HCC
                                                                                                   CIR vs. HCV
                                    ++              0          3           15         12           HCV vs. NL
                                    +++             0          0           3           3
           TRAIL                  Negative         18          12          9          14
                                     +              2          18          21         18           HCC vs. CIR
                                                                                                   HCC vs. HCV
                                    ++              0          0           0          18           HCV vs. NL
                                    +++             0          0           0          10
           RelA/p65               Negative         16          3           0          21
                                     +              4          18          9          19           CIR vs. HCC
                                                                                                   CIR vs. HCV
                                    ++              0          9           15         13           HCV vs. NL
                                    +++             0          0           6           7
           NFkB                   Negative         18          0           3          26
                                     +              2          6           18         22           CIR vs. HCC
                                                                                                   CIR vs. HCV
                                    ++              0          15          6          10           HCV vs. NL
                                    +++             0          9           3           2
           p53                    Negative         17          27          27         20
                                     +              3          3           3          26           HCC vs. CIR
                                                                                                   HCC vs. HCV
                                    ++              0          0           0          12           HCC vs. NL
                                    +++             0          0           0           2
           Cytoplasmic PHB        Negative         16          3           3          35
                                     +              4          5           7          23           CIR vs. HCC
                                                                                                   CIR vs. HCV
                                    ++              0          10          11          2           HCV vs. NL
                                    +++             0          12          9           0
           Nuclear PHB            Negative         18          27          24         19
                                     +              2          3           6          24           HCC vs. CIR
                                                                                                   HCC vs. HCV
                                    ++              0          0           0          13           HCC vs. NL
                                    +++             0          0           0           4
           TUNEL                  Negative         17          3           2           4
                                     +              3          16          18         15           HCC vs. CIR
                                                                                                   HCC vs. HCV
                                    ++              0          11          10         32           HCC vs. NL
                                    +++             0          0           0           9
           TNFR1: tumor necrosis factor receptor-1; TRAIL: TNF-related apoptosis-inducing ligand; NFkB: nuclear factor kappa B; PHB: prohibitin;
           TUNEL: transferase-mediated dUTP-biotin nick-end labelling; NL: normal liver; CIR: cirrhosis; HCV: hepatitis C virus; HCC: hepatocellular
           carcinoma
           The percentage of apoptosis was increased in HCC   hepatic cancer development, which is dependent
           [Figure 2L] in contrast to CIR [Figure 2K] and HCV   on different pathogenic mechanisms of the tumour
           [Figure 2J] (P = 0.0054 and P = 0.0217, respectively).   microenvironment.
           Moreover, the percentage of apoptosis was increased
           in HCV in relation to NL [Figure 2I] (P = 0.0161) [Figure 2O].  TNFα cytokine is increased in patients with chronic
                                                              HCV infection. [19]  TNFα and TNF-receptors levels
           DISCUSSION                                         are augmented during chronic HCV infection and
                                                              result in disease progression. [20]  Similarly, we found a
           The findings of the present study reveal the       progressive increase of TNFR1 expression in cases
           importance of p53 and PHB participation in human   of HCV and CIR in comparison to NL. Indeed, TNFα

                           Hepatoma Research ¦ Volume 3 ¦ February 28, 2017                                37
   40   41   42   43   44   45   46   47   48   49   50